HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
- 29 November 2011
- journal article
- review article
- Published by Wiley in Immunology & Cell Biology
- Vol. 90 (1), 85-94
- https://doi.org/10.1038/icb.2011.100
Abstract
Reversible acetylation mediated by histone deacetylases (HDACs) influences a broad repertoire of physiological processes, many of which are aberrantly controlled in tumor cells. As HDAC inhibition prompts tumor cells to enter apoptosis, small-molecule HDAC inhibitors have been developed as a new class of mechanism-based anti-cancer agent, many of which have entered clinical trials. Although the clinical picture is evolving and the precise utility of HDAC inhibitors remains to be determined, it is noteworthy that certain tumor types undergo a favorable response, in particular hematological malignancies. Vorinostat and romidepsin have been approved for treating cutaneous T-cell lymphoma in patients with progressive, persistent or recurrent disease. Here, we discuss developments in our understanding of molecular events that underlie the anti-cancer effects of HDAC inhibitors and relate this information to the emerging clinical picture for the application of these inhibitors in the treatment of cancer. Immunology and Cell Biology (2012) 90, 85-94; doi: 10.1038/icb.2011.100; published online 29 November 2011Keywords
Funding Information
- Cancer Research UK
- Medical Research Council
This publication has 122 references indexed in Scilit:
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancerBritish Journal of Cancer, 2011
- Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effectInvestigational New Drugs, 2010
- Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myelomaCancer, 2010
- Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumoursEuropean Journal of Cancer, 2010
- Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)Cancer, 2009
- HDAC expression and clinical prognosis in human malignanciesCancer Letters, 2008
- Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)Investigational New Drugs, 2008
- Deletion of Histone Deacetylase 3 Reveals Critical Roles in S Phase Progression and DNA Damage ControlMolecular Cell, 2008
- Chromatin Modifications and Their FunctionCell, 2007
- Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysisBreast Cancer Research and Treatment, 2005